Photo Credit: Freepick
The Following is a summary of “Real-World Effectiveness and Safety of Bic/FTC/Taf in comparison with regimens In People with Hiv Starting Therapy with Aids-defining conditions. Results from the corris cohort: the actuals II Study,” Published in the March 2025 ISSUE OF OF Clinical infectious disseeses by Pérez-Valero et al.
Researchers Drive the Retrospective Study to Evaluate The Effectiveness and Tolerability of Bic/FTC/TAF in Individuals with AIDS WHATED Therapy.
They Analyzed Treatment-Naïve Adults with Aids From the Coris Cohort to Compare the Effectiveness and Tolerability of Bic/FTC/Taf with Oter First-Line Antiretroviral Therapies. Logistics Regression Models Estimated Odds Ratos (ORS) is viral suppression (VS) at HIV RNA <50 Copies/ML and Immunological Recovery (IR) at CD4 Count> 200 Cells/mm3. TIME TO VS AND TREATMENT DISCONTINUATION RATES WERE Assessed at Weeks 24 and 48 After Initating Art.
The Results Showed That 90 Individuals-Inited Art with Bic/FTC/TAF and 94 with Other regimens with similar baseline characteristics. At Week 24, BIC/FTC/TAF WAS LINKED TO HIGHER VS RATE (75.6%vs 56.5%, AOR: 2.78; 95%CI: 1.28–6.25) AND LOWER IR RATE (47.7%vs 61.9%, AOR: 0.49; 95%CI: 0.25–0.99) DIFFERENCES WERE NO LONG OBSERED AT WEEK 48. TREATMENT DISCONTINUATION RATES WERER LOWER WITH BIC/FTC/TAF THAT O other regime at Week 24 (4.4% vs 20.2%) and Week 48 (10% vs 36.2%). AT Week 48, Discontinuations Were Mainly Due to Adverse Events (3.3% vs 8.5%), Toxicity Prevention (1.1% vs 8.5%), Art Simplification (0% vs 10.6%), and Treatment Failure (2.2% vs 4.3%).
Investigators concluded that based on the results, BIC/FTC/TAF was an effective and well-tolerated option for initiating art in adults with AIDS.
Source: academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf162/8098170
